西格列汀联合格列齐特缓释片对2型糖尿病患者血糖、血脂及胰岛β细胞功能的影响  

Effects of sitagliptin and gliclazide sustained-release tablets on blood glucose,blood lipids and islet β cell function in patients with type 2 diabetes mellitus

作　　者：焦杨[1] 丁石梅[1] 张静[1] 闫丽晶 李雪倩[1] 魏嘉 贺振甜 徐静[1] Jiao Yang;Ding Shimei;Zhang Jing;Yan Lijing;Li Xueqian;Wei Jia;He Zhentian;Xu Jing(Department of Endocrinology,Second Affiliated Hospital of Xi’an Jiaotong University,Xi’an,Shaanxi 710004,China)

机构地区：[1]西安交通大学第二附属医院内分泌科,西安710004

出　　处：《中华生物医学工程杂志》2020年第6期541-545,共5页Chinese Journal of Biomedical Engineering

基　　金：陕西省重点研发计划一般项目(2017SF-046)。

摘　　要：目的探讨西格列汀联合格列齐特缓释片对2型糖尿病(T2DM)患者血糖、血脂及胰岛β细胞功能的影响。方法纳入2017年10月至2019年10月本院收治的T2DM患者88例,随机分为对照组(n=44)和观察组(n=44)。对照组给予格列齐特缓释片治疗,观察组在对照组基础上加用西格列汀治疗。记录治疗前、治疗16周后两组血糖、糖化血红蛋白(HbA1c)、空腹胰岛素(FINS)、血脂、血清葡萄糖转运蛋白4(GLUT4)水平,检测两组胰岛β细胞功能及血管内皮功能变化。结果治疗后两组空腹血糖(FPG)、餐后2h血糖(2hPG)及HbA1c较治疗前降低,FINS较治疗前升高(均P<0.05)。治疗后两组血甘油三脂(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)较治疗前降低,高密度脂蛋白(HDL-C)较治疗前升高(均P<0.05)。治疗后两组稳态模型β细胞功能指数(HOMA-β)较治疗前升高,稳态模型胰岛素抵抗指数(HOMA-IR)较治疗前降低(均P<0.05)。治疗后观察组血清GLUT4水平高于治疗前,两组内皮依赖性血管舒张功能(EDD)较治疗前均显著增加,且治疗后观察组上述指标均显著优于对照组(均P<0.05)。结论西格列汀联合格列齐特缓释片治疗T2DM,能明显降低血糖水平,改善血脂异常和胰岛β细胞功能,修复血管内皮功能损伤,临床疗效确切。Objective To investigate the effects of sitagliptin and gliclazide sustained-release tablets on blood glucose,blood lipids and islet β-cell function in patients with type 2 diabetes(T2DM).Methods Eighty-eight patients with T2DM admitted to our hospital between October 2017 and October 2019 were randomly divided into the control group and study group(n=44 each).The control group was treated with gliclazide sustained-release tablets.In addition,the study group was treated with sitagliptin.The levels of blood glucose,glycated hemoglobin(HbA1c),fasting insulin(FINS),blood lipids,and serum glucose transporter 4(GLUT4)were recorded at baseline and at 16 weeks after the treatment in the two groups.The changes in isletβcell function and vascular endothelial function were examined in the two groups.Results After the treatment,the levels of fasting plasma glucose(FPG),postprandial 2 h plasma glucose(2hPG)and HbA1c in the two groups decreased compared with those at baseline,whereas the FINS increased compared with that at baseline(all P<0.05);the levels of plasma triglyceride(TG),total cholesterol(TC)and low-density lipoprotein cholesterol(LDL-C)in the two groups decreased compared with those at baseline,whereas the level of plasma high-density lipoprotein cholesterol(HDL-C)increased compared with that at baseline(all P<0.05);the homeostasis model assessment forβcell function(HOMA-β)index in the two groups increased compared with that at baseline,whereas the homeostasis model assessment for insulin resistance(HOMA-IR)index decreased compared with that at baseline(both P<0.05);the serum GLUT4 level was higher than that at baseline in the study group,and the endothelium-dependent dilation function(EDD)significantly increased compared with that at baseline in the two groups;and the indicators in the study group were significantly better than those in the control group(all P<0.05).Conclusion Sitagliptin and gliclazide sustained-release tablets in the treatment of T2DM may significantly reduce blood glucose level,improve dys

关 键 词：糖尿病 2型 西格列汀 格列齐特 血糖 血脂 

分 类 号：R587.1[医药卫生—内分泌]